Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 15/20 | 0.56 |
| ▸ | ACVR1B | P36896 | 14/20 | 0.56 |
| ▸ | ACVRL1 | P37023 | 13/20 | 0.56 |
| ▸ | BUB1 | O43683 | 4/20 | 0.49 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.48 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5954828 | 0.95 | TGFBR1 (0.60) | TGFBR1ACVR1BACVRL1BUB1BMPR1A | |
| SCHEMBL14223120 | 0.94 | TGFBR1 (0.56) | TGFBR1ACVR1BACVRL1BUB1BMPR1A | |
| SCHEMBL5954715 | 0.94 | TGFBR1 (0.58) | TGFBR1ACVR1BACVRL1BUB1BMPR1A | |
| SCHEMBL5954627 | 0.93 | TGFBR1 (0.57) | TGFBR1ACVR1BACVRL1BUB1BMPR1A | |
| SCHEMBL8348081 | 0.92 | TGFBR1 (0.58) | TGFBR1ACVR1BACVRL1BUB1BMPR1A | |
| SCHEMBL5954832 | 0.92 | TGFBR1 (0.58) | TGFBR1ACVR1BACVRL1BUB1BMPR1A | |
| SCHEMBL8347338 | 0.92 | TGFBR1 (0.59) | TGFBR1ACVR1BACVRL1BUB1BMPR1A | |
| SCHEMBL5955485 | 0.91 | TGFBR1 (0.54) | TGFBR1ACVR1BACVRL1BUB1BMPR1A | |
| SCHEMBL5955472 | 0.91 | TGFBR1 (0.54) | TGFBR1ACVR1BACVRL1BUB1BMPR1A | |
| SCHEMBL5955252 | 0.91 | TGFBR1 (0.56) | TGFBR1ACVR1BACVRL1BUB1BMPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9987277-B2 | Carboxamide 4-[(4-pyridyl)amino] pryimidines for the treatment of hepatitis C | JANSSEN SCIENCES IRELAND UC (IE) | 2018-06-05 | — | — | US | disclosed |
| US-9987277-B2 | Carboxamide 4-[(4-pyridyl)amino] pryimidines for the treatment of hepatitis C | JANSSEN SCIENCES IRELAND UC (IE) | 2018-06-05 | — | — | US | disclosed |
| US-9987277-B2 | Carboxamide 4-[(4-pyridyl)amino] pryimidines for the treatment of hepatitis C | JANSSEN SCIENCES IRELAND UC (IE) | 2018-06-05 | — | — | US | disclosed |
| EP-2097084-B1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO] PYRIMIDINES FOR THE TREATMENT OF HEPATITIS C | JANSSEN R & D IRELAND (IE) | 2015-01-28 | — | — | EP | disclosed |
| EP-2097084-B1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO] PYRIMIDINES FOR THE TREATMENT OF HEPATITIS C | JANSSEN R & D IRELAND (IE) | 2015-01-28 | — | — | EP | disclosed |
| US-20090247523-A1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-10-01 | — | — | US | disclosed |
| US-20090247523-A1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-10-01 | — | — | US | disclosed |
| US-20090247523-A1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-10-01 | — | — | US | disclosed |
| EP-2097084-A2 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO] PYRIMIDINES FOR THE TREATMENT OF HEPATITIS C | Tibotec Pharmaceuticals Ltd. (IE) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008040778-A2 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO] PYRIMIDINES FOR THE TREATMENT OF HEPATITIS C | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008040778-A2 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO] PYRIMIDINES FOR THE TREATMENT OF HEPATITIS C | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-04-10 | — | — | WO | disclosed |
| US-20060281763-A1 | Carboxamide inhibitors of TGFbeta | SCIOS INC. | 2006-12-14 | — | — | US | disclosed |
| WO-2006105222-A2 | CARBOXAMIDE INHIBITORS OF TGFB | SCIOS INC. (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247523-A1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS | HAVCR2, EIF2AK2, MAVS | TGFBR1 3765/4885ACVR1B 3981/4885ACVRL1 4277/4885 |
| US-20060281763-A1 | Carboxamide inhibitors of TGFbeta | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885ACVR1B 12/4885ACVRL1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.